These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 21967031

  • 1. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
    Cicero AF, Gerocarni B, Rosticci M, Borghi C.
    Clin Exp Hypertens; 2012; 34(2):113-7. PubMed ID: 21967031
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M.
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [Abstract] [Full Text] [Related]

  • 4. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
    Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ.
    Ren Fail; 2010 Jan; 32(2):192-7. PubMed ID: 20199181
    [Abstract] [Full Text] [Related]

  • 5. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S, Maki K, Aota Y, Sakuma T, Iwasaka T.
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [Abstract] [Full Text] [Related]

  • 6. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M, Pruijm M, Wuerzner G.
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home.
    Hashimoto J, Hirayama H, Hanasawa T, Watabe D, Asayama K, Metoki H, Kikuya M, Ohkubo T, Totsune K, Imai Y.
    Clin Exp Hypertens; 2005 May; 27(4):331-41. PubMed ID: 15921070
    [Abstract] [Full Text] [Related]

  • 8. Role of the fixed-dose combination lercanidipine-enalapril in renal protection.
    Egan CG, Pontremoli R.
    J Nephrol; 2011 May; 24(4):428-37. PubMed ID: 21279953
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension.
    Rump LC.
    Arzneimittelforschung; 2010 May; 60(3):124-30. PubMed ID: 20422943
    [Abstract] [Full Text] [Related]

  • 10. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies.
    Cleophas TJ, van Ouwerkerk BM, van der Meulen J, Zwinderman AH.
    Angiology; 2001 Jul; 52(7):469-75. PubMed ID: 11515986
    [Abstract] [Full Text] [Related]

  • 11. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
    Tocci G, Palano F, Pagannone E, Chin D, Ferrucci A, Volpe M.
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):115-23. PubMed ID: 19210207
    [Abstract] [Full Text] [Related]

  • 12. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD.
    Clin Ther; 1994 Feb; 16(3):490-504. PubMed ID: 7923316
    [Abstract] [Full Text] [Related]

  • 13. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
    Borghi C, Cicero AF.
    Clin Drug Investig; 2010 Feb; 30(12):843-54. PubMed ID: 20923243
    [Abstract] [Full Text] [Related]

  • 14. Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home.
    Hanazawa T, Obara T, Ogasawara K, Shinki T, Katada S, Inoue R, Metoki H, Asayama K, Kikuya M, Ohkubo T, Mano N, Imai Y.
    Clin Exp Hypertens; 2011 Feb; 33(7):427-36. PubMed ID: 21777149
    [Abstract] [Full Text] [Related]

  • 15. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [Abstract] [Full Text] [Related]

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 17. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [Abstract] [Full Text] [Related]

  • 18. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.
    Chatzikyrkou C, Haller H, Menne J.
    Expert Opin Pharmacother; 2009 Aug; 10(11):1833-40. PubMed ID: 19527194
    [Abstract] [Full Text] [Related]

  • 19. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE.
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [Abstract] [Full Text] [Related]

  • 20. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
    Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N.
    Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.